Biocon Limited has informed the Exchange regarding a press release dated October 16, 2025, titled "Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options".
Biocon Limited has informed the Exchange regarding a press release dated October 16, 2025, titled "Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options".